Nasopharyngeal Cancer Clinical Trial
Official title:
A Single-Arm Phase II Clinical Study of Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
Nasopharyngeal cancer is a malignant tumor that arises from the cells of the nasopharyngeal epithelium, with its occurrence spread across different regions worldwide. Recent data from China in 2015 revealed approximately 6.0 million new cases of nasopharyngeal cancer, leading to approximately 34,000 deaths. When choosing a chemotherapy regimen for patients with metastatic nasopharyngeal cancer, the gemcitabine and cisplatin combination (GP) is typically recommended as the initial treatment. However, it is common for patients to experience disease progression after receiving first-line chemotherapy, highlighting the importance of a well-defined second-line treatment plan. Recent clinical studies have indicated that combining nituzumab with radiotherapy can enhance treatment efficacy with minimal side effects, providing promising results for advanced nasopharyngeal cancer patients. Additionally, the use of irinotecan liposome injection has proved beneficial in modifying the drug's pharmacokinetics, resulting in improved drug delivery to the tumor site while reducing toxicity in healthy tissues. This study aims to explore the effectiveness and safety of combining irinotecan liposome with nituzumab treatment for recurrent metastatic nasopharyngeal carcinoma that has not responded to initial immunotherapy. Participants selected for this clinical trial will receive a treatment regimen consisting of liposomal irinotecan administered intravenously at a dose of 70 mg/m2 on day 1, along with nituzumab given at a dose of 400 mg via intravenous injection on the same day. This treatment cycle will be repeated every two weeks for a maximum of eight cycles, or until disease progression, intolerable side effects, or other criteria necessitating discontinuation of treatment as determined by the investigator. By evaluating the efficacy and safety of this combined regimen, investigators aim to establish a novel therapeutic approach for managing advanced nasopharyngeal carcinoma in the context of current immunotherapy advancements.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00370890 -
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 3 | |
| Recruiting |
NCT04340024 -
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
|
||
| Completed |
NCT00697619 -
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT00078546 -
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
|
Phase 1 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT01074021 -
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03890185 -
Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC
|
Phase 2 | |
| Not yet recruiting |
NCT04158414 -
Applying PET/MR in Oncology - a Prospective Project
|
N/A | |
| Completed |
NCT02608073 -
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT03656250 -
Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
|
||
| Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
| Recruiting |
NCT04476641 -
A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Recruiting |
NCT03003182 -
A Study of Nasopharyngeal Carcinoma From Guangdong
|
N/A | |
| Not yet recruiting |
NCT06349889 -
Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05305131 -
Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT01800071 -
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
|
Phase 1 | |
| Recruiting |
NCT00304694 -
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
|
N/A | |
| Recruiting |
NCT05638269 -
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
|